X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-partners-with-pfizer-to-launch-abrocitinib-in-india-to-treat-atopic-dermatitis/articleshow/107296402.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.businesswire.com/news/home/20230210005281/en/FDA-Approves-Pfizers-Supplemental-New-Drug-Application-for-CIBINQO%C2%AE-abrocitinib
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/
https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/
https://endpts.com/ema-limits-use-of-jak-inhibitors-for-at-risk-groups-in-wake-of-safety-concerns/
https://www.pharmatimes.com/news/nice_recommends_use_of_leo_pharmas_adtralza_1451607
https://www.biospace.com/article/releases/health-canada-approves-the-use-of-cibinqo-abrocitinib-for-the-treatment-of-patients-12-with-moderate-to-severe-atopic-dermatitis/
http://www.pharmafile.com/news/664356/nice-recommends-dermatitis-treatment-use-nhs-england-and-wales
https://endpts.com/a-3b-peak-sales-win-pfizer-thinks-so-as-fda-offers-a-green-light-to-its-jak1-drug-abrocitinib/
http://www.pharmafile.com/news/599719/european-commission-approves-pfizer-drug-adults-moderate-severe-atopic-dermatitis
https://www.pharmatimes.com/news/european_commission_approves_pfizers_atopic_dermatitis_treatment_1385143
https://www.fiercepharma.com/pharma/pfizer-filings-further-pushed-back-as-jak-drugs-fall-victim-to-fda-s-protracted-safety
http://www.pharmatimes.com/news/patients_gain_early_access_to_pfizers_atopic_dermatitis_drug_1362635
https://endpts.com/pfizer-still-chasing-dupixent-releases-fifth-round-of-data-for-eczema-jak-inhibitor-abrocitinib/
https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory
https://www.fiercebiotech.com/biotech/pfizer-tips-pipeline-to-add-15b-to-sales-coming-years
https://www.fiercebiotech.com/biotech/safety-issues-for-pfizer-s-dupixent-rival-may-give-prescribers-pause
http://www.pharmatimes.com/news/pfizers_abrocitinib_hits_endpoints_in_late-stage_atopic_dermatitis_study_1329548
Market Place
Share 
